These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 21047595)
21. The Japanese guideline for prostate cancer screening. Hamashima C; Nakayama T; Sagawa M; Saito H; Sobue T Jpn J Clin Oncol; 2009 Jun; 39(6):339-51. PubMed ID: 19346535 [TBL] [Abstract][Full Text] [Related]
22. Perspective on prostate cancer screening. Rogers CS Int J Clin Pract; 2011 Jan; 65(1):31-4. PubMed ID: 21155942 [No Abstract] [Full Text] [Related]
23. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010. ; Int J Urol; 2010 Oct; 17(10):830-8. PubMed ID: 20825509 [TBL] [Abstract][Full Text] [Related]
24. The phantom menace of prostate cancer screening. Ghani KR; Trinh QD; Menon M BJU Int; 2012 Feb; 109(3):324-6. PubMed ID: 22243666 [No Abstract] [Full Text] [Related]
25. American Cancer Society guideline for the early detection of prostate cancer: update 2010. Wolf AM; Wender RC; Etzioni RB; Thompson IM; D'Amico AV; Volk RJ; Brooks DD; Dash C; Guessous I; Andrews K; DeSantis C; Smith RA; CA Cancer J Clin; 2010; 60(2):70-98. PubMed ID: 20200110 [TBL] [Abstract][Full Text] [Related]
26. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Schröder FH Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469 [TBL] [Abstract][Full Text] [Related]
27. Summaries for patients. Screening smarter, not harder, for prostate cancer. Ann Intern Med; 2013 Feb; 158(3):I-30. PubMed ID: 23381056 [No Abstract] [Full Text] [Related]
28. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Bray F; Lortet-Tieulent J; Ferlay J; Forman D; Auvinen A Eur J Cancer; 2010 Nov; 46(17):3040-52. PubMed ID: 21047585 [TBL] [Abstract][Full Text] [Related]
29. Balancing the harms and benefits of early detection of prostate cancer. van Leeuwen PJ; Connolly D; Tammela TL; Auvinen A; Kranse R; Roobol MJ; Schroder FH; Gavin A Cancer; 2010 Oct; 116(20):4857-65. PubMed ID: 20839233 [TBL] [Abstract][Full Text] [Related]
30. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586 [TBL] [Abstract][Full Text] [Related]
31. Screening for prostate cancer remains controversial. Stark JR; Mucci L; Rothman KJ; Adami HO BMJ; 2009 Sep; 339():b3601. PubMed ID: 19778971 [No Abstract] [Full Text] [Related]
32. Prostate cancer and prostate-specific antigen (PSA) screening in Austria. Vutuc C; Schernhammer ES; Haidinger G; Waldhör T Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872 [TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians. Kell JS Can J Urol; 2010 Feb; 17 Suppl 1():18-25. PubMed ID: 20170597 [TBL] [Abstract][Full Text] [Related]
34. Prostate-specific antigen testing and prostate cancer screening. Djavan B; Eckersberger E; Finkelstein J; Sadri H; Taneja SS; Lepor H Prim Care; 2010 Sep; 37(3):441-59, vii. PubMed ID: 20705192 [TBL] [Abstract][Full Text] [Related]
35. Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Terris MK Eur Urol; 2009 Feb; 55(2):392; discussion 393. PubMed ID: 18353530 [No Abstract] [Full Text] [Related]
36. Correlation between stage shift and differences in mortality in the European Randomised study of Screening for Prostate Cancer (ERSPC). Bokhorst LP; Zappa M; Carlsson SV; Kwiatkowski M; Denis L; Paez A; Hugosson J; Moss S; Auvinen A; Roobol MJ BJU Int; 2016 Nov; 118(5):677-680. PubMed ID: 27104278 [TBL] [Abstract][Full Text] [Related]
37. Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees. Bergdahl AG; Aus G; Lilja H; Hugosson J Cancer; 2009 Dec; 115(24):5672-9. PubMed ID: 19813273 [TBL] [Abstract][Full Text] [Related]
38. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878 [TBL] [Abstract][Full Text] [Related]
39. Efficacy vs effectiveness in prostate-specific antigen screening. Albertsen PC J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583 [No Abstract] [Full Text] [Related]
40. [PSA related screening of prostate cancer. Panic or improvement?]. Fornara P; Jurczok A Aktuelle Urol; 2004 Feb; 35(1):43-8. PubMed ID: 14997414 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]